Skip to main content

PAPEL DE IDE EN EL ACLARAMIENTO Y LA ACCION DE LA INSULINA EN EL HIGADO

PID2019-110496RB-C22

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hepatic insulin-degrading enzyme regulates glucose and insulin homeostasis in diet-induced obese mice

  • Merino, Beatriz
  • Fernández-Díez, Cristina
  • Parrado-Fernández, Cristina
  • González-Casimiro, Carlos M.
  • Postigo-Casado, Tamara
  • Lobatón, Carmen D.
  • Leissring, Malcolm A.
  • Cózar-Castellano, Irene
  • Perdomo, Germán
© 2020 The Authors., The insulin-degrading enzyme (IDE) is a metalloendopeptidase with a high affinity for insulin. Human genetic polymorphisms in Ide have been linked to increased risk for T2DM. In mice, hepatic Ide ablation causes glucose intolerance and insulin resistance when mice are fed a regular diet. [Objective]: These studies were undertaken to further investigate its regulatory role in glucose homeostasis and insulin sensitivity in diet-induced obesity. [Methods]: To this end, we have compared the metabolic effects of loss versus gain of IDE function in mice fed a high-fat diet (HFD). [Results]: We demonstrate that loss of IDE function in liver (L-IDE-KO mouse) exacerbates hyperinsulinemia and insulin resistance without changes in insulin clearance but in parallel to an increase in pancreatic β-cell function. Insulin resistance was associated with increased FoxO1 activation and a ~2-fold increase of GLUT2 protein levels in the liver of HFD-fed mice in response to an intraperitoneal injection of insulin. Conversely, gain of IDE function (adenoviral delivery) improves glucose tolerance and insulin sensitivity, in parallel to a reciprocal ~2-fold reduction in hepatic GLUT2 protein levels. Furthermore, in response to insulin, IDE co-immunoprecipitates with the insulin receptor in liver lysates of mice with adenoviral-mediated liver overexpression of IDE. [Conclusions]: We conclude that IDE regulates hepatic insulin action and whole-body glucose metabolism in diet-induced obesity via insulin receptor levels., This work was supported by grants from the Ministerio de Economía, Industria y Competitividad: SAF2016-77871-C2-1-R to IC; SAF2016-77871-C2-2-R to GP; This work was supported by grants from the Ministerio de Ciencia e Innovación PID2019-110496RB-C21 to IC; PID2019-110496RB-C22 to GP. European Foundation for the Study of Diabetes (European Diabetes Research Programme on New Targets for Type 2 Diabetes supported by MSD-2017) to IC and GP. The project leading to these results has received funding from “la Caixa” Foundation, under agreement LCF/PR/PR18/51130007 to GP. This work was suppoted by grant from NIH GM115617 to ML.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme

  • González Casimiro, Carlos M.
  • Merino, Beatriz
  • Casanueva-Álvarez, Elena
  • Postigo-Casado, Tamara
  • Cámara-Torres, Patricia
  • Fernández-Díez, Cristina
  • Leissring, Malcolm A.
  • Cózar-Castellano, Irene
  • Perdomo, Germán
Insulin-degrading enzyme (IDE) is a highly conserved and ubiquitously expressed metalloprotease that degrades insulin and several other intermediate-size peptides. For many decades, IDE had been assumed to be involved primarily in hepatic insulin clearance, a key process that regulates availability of circulating insulin levels for peripheral tissues. Emerging evidence, however, suggests that IDE has several other important physiological functions relevant to glucose and insulin homeostasis, including the regulation of insulin secretion from pancreatic β-cells. Investigation of mice with tissue-specific genetic deletion of <i>Ide</i> in the liver and pancreatic β-cells (L-IDE-KO and B-IDE-KO mice, respectively) has revealed additional roles for IDE in the regulation of hepatic insulin action and sensitivity. In this review, we discuss current knowledge about IDE’s function as a regulator of insulin secretion and hepatic insulin sensitivity, both evaluating the classical view of IDE as an insulin protease and also exploring evidence for several non-proteolytic functions. Insulin proteostasis and insulin sensitivity have both been highlighted as targets controlling blood sugar levels in type 2 diabetes, so a clearer understanding the physiological functions of IDE in pancreas and liver could led to the development of novel therapeutics for the treatment of this disease., This research was funded by the Ministerio de Economía, Industria y Competitividad, grant numbers SAF2016-77871-C2-1-R to I.C.-C.; SAF2016-77871-C2-2-R to G.P.; Ministerio de Ciencia e Innovación PID2019-110496RB-C21 to I.C.-C.; PID2019-110496RB-C22 to G.P.; European Foundation for the Study of Diabetes (European Diabetes Research Programme on New Targets for Type 2 Diabetes supported by MSD-2017) to I.C.-C. and G.P.; and the US National Institutes of Health (GM115617) to M.A.L. The project leading to these results has received funding from “la Caixa” Foundation, under agreement LCF/PR/PR18/51130007 to G.P., C.M.G.-C. and E.C.-Á. were supported by fellowships from the Junta de Castilla y León and the European Social Fund (ORDER EDU/574/2018 and ORDER EDU/556/2019, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting Insulin-Degrading Enzyme in Insulin Clearance

  • Leissring, Malcolm A.
  • González-Casimiro, Carlos M.
  • Merino, Beatriz
  • Suire, Caitlin N.
  • Perdomo, Germán
© 2021 by the authors., Hepatic insulin clearance, a physiological process that in response to nutritional cues clears ~50–80% of circulating insulin, is emerging as an important factor in our understanding of the pathogenesis of type 2 diabetes mellitus (T2DM). Insulin-degrading enzyme (IDE) is a highly conserved Zn2+-metalloprotease that degrades insulin and several other intermediate-size peptides. Both, insulin clearance and IDE activity are reduced in diabetic patients, albeit the cause-effect relationship in humans remains unproven. Because historically IDE has been proposed as the main enzyme involved in insulin degradation, efforts in the development of IDE inhibitors as therapeutics in diabetic patients has attracted attention during the last decades. In this review, we retrace the path from Mirsky’s seminal discovery of IDE to the present, highlighting the pros and cons of the development of IDE inhibitors as a pharmacological approach to treating diabetic patients., This research was funded by the Ministerio de Economía, Industria y Competitividad, grant number SAF2016-77871-C2-2-R to G.P.; Ministerio de Ciencia e Innovación PID2019-110496RB-C22 to G.P.; European Foundation for the Study of Diabetes (European Diabetes Research Programme on New Targets for Type 2 Diabetes supported by MSD-2017) to G.P.; European Foundation for the Study of Diabetes (EFSD) -Novo Nordisk to B.M.; and the US National Institutes of Health (GM115617) to M.A.L. The project leading to these results has received funding from “La Caixa” Foundation, under agreement LCF/PR/PR18/51130007 to G.P. C.M.G.-C. was supported by a fellowship from the Junta de Castilla y León and the European Social Fund (ORDER EDU/574/2018). B.M. was supported by a “Rising Star” fellowship (EFSD-Novo Nordisk).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effects of Fasting and Feeding on Transcriptional and Posttranscriptional Regulation of Insulin-Degrading Enzyme in Mice

  • González-Casimiro, Carlos M.
  • Cámara-Torres, Patricia
  • Merino, Beatriz
  • Diez-Hermano, Sergio
  • Postigo-Casado, Tamara
  • Leissring, Malcolm A.
  • Cózar-Castellano, Irene
  • Perdomo, Germán
© 2021 by the authors., Insulin-degrading enzyme (IDE) is a highly conserved and ubiquitously expressed Zn2+-metallopeptidase that regulates hepatic insulin sensitivity, albeit its regulation in response to the fasting-to-postprandial transition is poorly understood. In this work, we studied the regulation of IDE mRNA and protein levels as well as its proteolytic activity in the liver, skeletal muscle, and kidneys under fasting (18 h) and refeeding (30 min and 3 h) conditions, in mice fed a standard (SD) or high-fat (HFD) diets. In the liver of mice fed an HFD, fasting reduced IDE protein levels (~30%); whereas refeeding increased its activity (~45%) in both mice fed an SD and HFD. Likewise, IDE protein levels were reduced in the skeletal muscle (~30%) of mice fed an HFD during the fasting state. Circulating lactate concentrations directly correlated with hepatic IDE activity and protein levels. Of note, L-lactate in liver lysates augmented IDE activity in a dose-dependent manner. Additionally, IDE protein levels in liver and muscle tissues, but not its activity, inversely correlated (R2 = 0.3734 and 0.2951, respectively; p < 0.01) with a surrogate marker of insulin resistance (HOMA index). Finally, a multivariate analysis suggests that circulating insulin, glucose, non-esterified fatty acids, and lactate levels might be important in regulating IDE in liver and muscle tissues. Our results highlight that the nutritional regulation of IDE in liver and skeletal muscle is more complex than previously expected in mice, and that fasting/refeeding does not strongly influence the regulation of renal IDE., This research was funded by Ministerio de Economía, Industria y Competitividad, grants numbers SAF2016-77871-C2-1-R to I.C.-C. and SAF2016-77871-C2-2-R to G.P. Ministerio de Ciencia e Innovación PID2019-110496RB-C21 to I.C.-C. and PID2019-110496RB-C22 to G.P.; European Foundation for the Study of Diabetes (European Diabetes Research Programme on New Targets for Type 2 Diabetes supported by MSD-2017) to I.C.-C. and G.P.; European Foundation for the Study of Diabetes Rising Star Fellowship Programme supported by EFSD-Novo Nordisk and Sociedad Española de Diabetes (SED) Young Basic Researchers grant to B.M.; and U.S. National Institutes of Health GM115617 to M.A.L. The project leading to these results has received funding from “La Caixa” Foundation, under agreement LCF/PR/PR18/51130007 to G.P. This research was funded by Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Escalera de Excelencia, Junta de Castilla y León (Ref. CLU-2019-02). C.M.G.-C. was supported by a fellowship from the Junta de Castilla y León and the European Social Fund (ORDER EDU/574/2018).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Altered surface expression of insulin-degrading enzyme on monocytes and lymphocytes from COVID-19 patients both at diagnosis and after hospital discharge

  • González-Casimiro, Carlos M.
  • Arribas, Elisa
  • Fiz-López, Aida
  • Casas, Javier
  • Gutiérrez, Sara
  • Tellería, Pablo
  • Novoa, Cristina
  • Rojo-Rello, Silvia
  • Tamayo, Eduardo
  • Orduña, Antonio
  • Dueñas, Carlos
  • Bernardo, David
  • Perdomo, Germán
Although the COVID-19 disease has developed into a worldwide pandemic, its pathophysiology remains to be fully understood. Insulin-degrading enzyme (IDE), a zinc-metalloprotease with a high affinity for insulin, has been found in the interactomes of multiple SARS-CoV-2 proteins. However, the relevance of IDE in the innate and adaptative immune responses elicited by circulating peripheral blood mononuclear cells is unknown. Here, we show that IDE is highly expressed on the surface of circulating monocytes, T-cells (both CD4+ and CD4−), and, to a lower extent, in B-cells from healthy controls. Notably, IDE’s surface expression was upregulated on monocytes from COVID-19 patients at diagnosis, and it was increased in more severe patients. However, IDE’s surface expression was downregulated (relative to healthy controls) 3 months after hospital discharge in all the studied immune subsets, with this effect being more pronounced in males than in females, and thus it was sex-dependent. Additionally, IDE levels in monocytes, CD4+ T-cells, and CD4− T-cells were inversely correlated with circulating insulin levels in COVID-19 patients (both at diagnosis and after hospital discharge). Of note, high glucose and insulin levels downregulated IDE surface expression by ~30% in the monocytes isolated from healthy donors, without affecting its expression in CD4+ T-cells and CD4− T-cells. In conclusion, our studies reveal the sex- and metabolism-dependent regulation of IDE in monocytes, suggesting that its regulation might be important for the recruitment of immune cells to the site of infection, as well as for glucometabolic control, in COVID-19 patients., This work was funded by the European Commission–NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global) and Junta de Castilla y León (Proyectos COVID 07.04.467B04.74011.0) to D.B. The project leading to these results had received funding from the “La Caixa” Foundation under agreement LCF/PR/PR18/51130007 to G.P. and grant PID2019-110496RB-C22 funded by MCIN/AEI/10.13039/501100011033 to G.P. This research was funded by the Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Junta de León and the European Social Fund (ORDER EDU/574/2018).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation

  • Merino, Beatriz
  • Casanueva-Álvarez, Elena
  • Quesada, Iván
  • González-Casimiro, Carlos M.
  • Fernández-Díez, Cristina
  • Postigo-Casado, Tamara
  • Leissring, Malcolm A.
  • Kaestner, K.
  • Perdomo, Germán
  • Cózar-Castellano, Irene
[Aims/hypothesis]: Type 2 diabetes is characterised by hyperglucagonaemia and perturbed function of pancreatic glucagon-secreting alpha cells but the molecular mechanisms contributing to these phenotypes are poorly understood. Insulin-degrading enzyme (IDE) is present within all islet cells, mostly in alpha cells, in both mice and humans. Furthermore, IDE can degrade glucagon as well as insulin, suggesting that IDE may play an important role in alpha cell function in vivo. [Methods]: We have generated and characterised a novel mouse model with alpha cell-specific deletion of Ide, the A-IDE-KO mouse line. Glucose metabolism and glucagon secretion in vivo was characterised; isolated islets were tested for glucagon and insulin secretion; alpha cell mass, alpha cell proliferation and α-synuclein levels were determined in pancreas sections by immunostaining. [Results]: Targeted deletion of Ide exclusively in alpha cells triggers hyperglucagonaemia and alpha cell hyperplasia, resulting in elevated constitutive glucagon secretion. The hyperglucagonaemia is attributable in part to dysregulation of glucagon secretion, specifically an impaired ability of IDE-deficient alpha cells to suppress glucagon release in the presence of high glucose or insulin. IDE deficiency also leads to α-synuclein aggregation in alpha cells, which may contribute to impaired glucagon secretion via cytoskeletal dysfunction. We showed further that IDE deficiency triggers impairments in cilia formation, inducing alpha cell hyperplasia and possibly also contributing to dysregulated glucagon secretion and hyperglucagonaemia. [Conclusions/interpretation]: We propose that loss of IDE function in alpha cells contributes to hyperglucagonaemia in type 2 diabetes., This work was supported by the following grants: Ministerio de Economía, Industria y Competitividad from Spain (SAF2016-77871-C2-1-R to IC and BFU2016-77125-R to IQ); Ministerio de Ciencia y Universidades from Spain (PID2019-110496RB-C21 to IC and PID2019-110496RB-C22 to GP); ‘La Caixa’ Foundation (grant LCF/PR/PR18/51130007 to GP); European Foundation for the Study of Diabetes Rising Star Fellowship (to BM), supported by EFSD-Novo Nordisk; Sociedad Española de Diabetes (SED) Grant to young basic researchers 2021 (to BM); and National Institutes of Health from USA (GM115617 to MAL). This research was funded by Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Escalera de Excelencia, Junta de Castilla y León (Ref. CLU-2019-02). CMG and EC were supported by fellowships from the Junta de Castilla y León and the European Social Fund (ORDER EDU/574/2018 and ORDER EDU/556/2019, respectively).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Primary Cilia in Pancreatic ß- and ¿-Cells: Time to Revisit the Role of Insulin-Degrading Enzyme

  • Pablos, Marta
  • Casanueva-Álvarez, Elena
  • González-Casimiro, Carlos M.
  • Merino, Beatriz
  • Perdomo, Germán
  • Cózar-Castellano, Irene
The primary cilium is a narrow organelle located at the surface of the cell in contact with the extracellular environment. Once underappreciated, now is thought to efficiently sense external environmental cues and mediate cell-to-cell communication, because many receptors, ion channels, and signaling molecules are highly or differentially expressed in primary cilium. Rare genetic disorders that affect cilia integrity and function, such as Bardet-Biedl syndrome and Alström syndrome, have awoken interest in studying the biology of cilium. In this review, we discuss recent evidence suggesting emerging roles of primary cilium and cilia-mediated signaling pathways in the regulation of pancreatic β- and α-cell functions, and its implications in regulating glucose homeostasis, The project leading to this Review has received funding from “La Caixa” Foundation, under agreement LCF/PR/PR18/51130007 to GP; Grants PID2019-110496RB-C21 and PID2019-110496RB-C22 funded by MCIN/AEI/10.13039/501100011033 to IC-C and GP, respectively; European Foundation for the Study of Diabetes Rising Star Fellowship to BM supported by EFSD-Novo Nordisk; This research was funded by the Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Junta de Castilla y León (CCVC8485). CG-C and EC-Á were supported by a fellowship from the Junta de Castilla y León and the European Social Fund (ORDER EDU/574/2018 and ORDER EDU/556/2019, respectively).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Decreased expression of insulin-degrading enzyme increases gluconeogenesis and glucose production in cultured hepatocytes administered with glucagon

  • González-Casimiro, Carlos M.
  • Cámara-Torres, Patricia
  • Merino, Beatriz
  • Astudillo, Alma M.
  • Fuente, Miguel A. de la
  • Ramírez, Cristina
  • Alonso, Andrés
  • Cózar-Castellano, Irene
  • Perdomo, Germán
Insulin-degrading enzyme (IDE) is a protein with proteolytic and non-proteolytic functions that regulates glucose homeostasis. In the fasted state, glucagon regulates glycemia through induction of hepatic gluconeogenesis. The rate of hepatic gluconeogenesis is elevated in subjects with type 2 diabetes (T2D) compared with healthy subjects. Interestingly, subjects with T2D show decreased expression of hepatic IDE. However, the role of IDE on the regulation of hepatic gluconeogenesis is completely unknow. We hypothesize that IDE deficiency alters glucagon signaling and thereby gluconeogenesis. To test this hypothesis, we used mouse liver tissues and cultured hepatocytes with total or partial IDE deficiency. The glucagon signaling pathway, expression of gluconeogenic genes, glucose production, and transcriptomic analysis were performed in control and IDE-KO hepatocytes. Total or partial loss of IDE in liver tissues or cultured mouse hepatocytes resulted in lower levels of the glucagon receptor (GCGR) and the cAMP-response element binding protein (CREB). However, glucagon stimulation increased the phosphorylation of CREB, despite lower levels of cAMP in IDE-deficient mouse hepatocytes. The activation of CREB was associated with an upregulation of the gluconeogenic genes Pck1 and G6pc (~ 200% and ~ 70% respectively) and higher glucose production in IDE-deficient mouse hepatocytes. Finally, genetic depletion of IDE in HepG2 hepatocytes led to upregulation of genes involved in cellular functions related to membranes, organelles and signaling receptors. These findings may be of relevance to better understand the regulation of hepatic gluconeogenesis and the use of IDE as a potential therapeutic target for the treatment of T2D., This work was supported by grants PID2019-110496RB-C21 and PID2022-136605OB-C21 to ICC; PID2019-110496RB-C22 and PID2022-136605OB-C22 to GP funded by MCIN/AEI/https://doi.org/10.13039/501100011033 “ERDF A way of making Europe”; CGC was supported by fellowship from the Junta de Castilla y León and the European Social Fund (ORDER EDU/574/2018); PCT was supported by fellowship from the Universidad de Valladolid 2020, co-funded by Banco Santander., Peer reviewed